VISACards AcceptedFree Shipping Over $300GTA Third-Party TestedHPLC Purity and Bacterial Endotoxin TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% OffVISACards AcceptedFree Shipping Over $300GTA Third-Party TestedHPLC Purity and Bacterial Endotoxin TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% Off
Out of stock

FRAG 176-191

10 mg (lyophilized)

Purity:

≥99% (HPLC)

FRAG 176-191 10 mg (lyophilized) research vial

Cap colour is for illustration purposes only

Research peptide · RUO · Canada

FRAG 176-191

10 mg (lyophilized)

Formula
N/ACAD · per vial

+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer · VISA

1
Inquire
Purity≥99% (HPLC)
Storage-20°C
FormLyophilized
TestingHPLC
🏦Interac e-Transfer
COA policy·Returns

About this compound

HGH Fragment 176-191 (FRAG 176-191) is a synthetic peptide corresponding to the C-terminal amino acid sequence 176–191 of human growth hormone (hGH). This region of the hGH molecule is believed to be responsible for the lipolytic (fat-burning) activity of the full-length hormone, while being devoid of the growth-promoting and insulin-desensitizing effects associated with intact hGH. FRAG 176-191 acts by mimicking the way natural growth hormone regulates fat metabolism, stimulating lipolysis and inhibiting lipogenesis without significantly affecting blood glucose or promoting cell proliferation. Preclinical research has examined FRAG 176-191 primarily in rodent obesity and metabolic models as a selective lipolytic tool compound.

Storage and handling

Lyophilized storage

Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.

Preclinical research references

Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.

  • Obese rodent models demonstrated that FRAG 176-191 administration produced significant reductions in body fat mass and adipose tissue weight compared to vehicle controls, with effects attributed to enhanced lipolysis in white adipose tissue without stimulating linear growth (Ng et al., 2000)
  • In vitro adipocyte studies showed FRAG 176-191 inhibited lipogenesis and stimulated lipolysis in isolated fat cell preparations, with mechanistic studies suggesting involvement of β3-adrenergic receptor-independent pathways in adipose tissue (Heffernan et al., 2001)
  • Rat metabolic studies confirmed that FRAG 176-191 did not significantly alter fasting insulin levels or glucose tolerance at lipolytically active doses, supporting its selectivity for fat metabolism pathways over the diabetogenic effects associated with full-length hGH administration (Ng et al., 2000)

Shipping & returns

Shipping

1–5 business days (5–7 for BC, NL and remote areas), Canada-wide tracked courier, double tamper-proof packaging.

Returns

All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.

Quality assurance

Every batch independently tested for purity. COA on file and available before purchase.

FAQ — FRAG 176-191

For research use only. Not for human or veterinary administration.

Research updates

Stay ahead of new batches.

New compounds, COA releases, batch testing results, and research content — straight to your inbox.

Research Use Only (RUO): All products are strictly for laboratory research. Not for human or veterinary use. Full disclaimer →